<DOC>
	<DOC>NCT00463541</DOC>
	<brief_summary>To evaluate the safety and efficacy of solifenacin succinate in subjects with overactive bladder symptoms (urgency, with or without urge incontinence, usually with frequency and nocturia).</brief_summary>
	<brief_title>Open-label Study of the Efficacy and Safety of VESIcare® in Patients With Overactive Bladder Symptoms</brief_title>
	<detailed_description>Study included a 24 week extension that did not occur due to FDA approval of the product.</detailed_description>
	<mesh_term>Urinary Bladder, Overactive</mesh_term>
	<mesh_term>Solifenacin Succinate</mesh_term>
	<criteria>Symptoms of OAB (urgency, with or without urge incontinence, usually with frequency and nocturia) for ≥3 or more months. Patients may be included if they are on another OAB medication; however, patients must washout from other OAB medications for at least 7 days prior to receiving solifenacin succinate. Previous nondrug treatment of OAB is allowed if it has been established at least 4 weeks prior to study entry and is continued throughout the study. Significant stress incontinence or mixed stress/urge incontinence where stress is the predominant factor Evidence of urinary tract infection; chronic inflammation such as interstitial cystitis and bladder stones Clinically significant outflow obstruction (benign prostatic hyperplasia)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Urinary Bladder, Overactive</keyword>
	<keyword>Urgency</keyword>
	<keyword>VESIcare®</keyword>
	<keyword>Solifenacin succinate</keyword>
</DOC>